AlanLeeMD
Radiation Oncology • Los Angeles, CAGynecologic Cancer, Ocular Radiation Oncology, Thoracic Cancer, Urologic Cancer
Clinical Assistant Professor
Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Medical Plaza
Suite #B265
Los Angeles, CA 90095Phone+1 310-825-9775Fax+1 310-825-9775
Summary
- Dr. Alan Lee is a radiation oncologist in Los Angeles, CA. He received his medical degree from State University of New York Upstate Medical University and has been in practice 2 years. He also speaks multiple languages, including Chinese (Mandarin). He specializes in gynecologic, and urologic cancer. Clinically experienced in external beam radiotherapy (IMRT/SBRT/SRS), and high-dose rate (HDR) brachytherapy.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Radiation Oncology, 2018 - 2019
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Radiation Oncology, 2014 - 2018
Newton-Wellesley HospitalInternship, Transitional Year, 2013 - 2014
SUNY Upstate Medical UniversityClass of 2013
Certifications & Licensure
CA State Medical License 2018 - 2026
MA State Medical License 2013 - 2014- American Board of Radiology Radiation Oncology
- Institute for Healthcare ImprovementBasic Certification
Publications & Presentations
PubMed
- 6 citationsEvaluating the natural growth rate of metastatic cancer to the brain.Andrew J. Kobets, Reid Backus, Rose Fluss, Alan Lee, Patrick LaSala
Surgical Neurology International. 2020-08-21 - 2 citationsHigh-Dose Rate Interstitial Spine Brachytherapy Using an Intraoperative Mobile Computed Tomography-Guided Surgical Navigation System.Rogelio Medina, Luke Macyszyn, Andrew S Lim, Mark A. Attiah, Kayla Kafka-Peterson
Operative Neurosurgery. 2021-11-15 - 8 citationsSafety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-S...Trudy C Wu, Annalise Stube, Carol Felix, Denise Oseguera, Tahmineh Romero
International Journal of Radiation Oncology, Biology, Physics. 2023-09-01
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
